AI in Biopharma Innovation and Regulatory Cha...

Enterprise leaders face a growing gap between AI ambition and the fragmented data, legacy systems, and cultural friction that prevent pilots from becoming scalable value. In this episode, Julian Tang, Chief Operations Officer for the Innovation Office at BlackRock, examines how u ...  Show more

Virtual cell models promise faster, cheaper early-stage drug discovery. However, the industry still lacks a shared way to judge which of these models can actually be trusted on a given problem. In this episode, Kristóf Szalay, CTO and Co-Founder of Turbine, and Gerold Csendes, Sc ...  Show more

Daphne Koller is the founder and CEO of insitro, a company using AI and machine learning to engineer drug discovery. In this conversation with a16z's Vijay Pande, she discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultura ...  Show more

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ...  Show more

Vaccine-maker Moderna is also a data company, and that’s enabling it to use AI to drastically reduce drug-development times, Chief Information Officer Brad Miller tells Bloomberg Intelligence’s Sam Fazeli and Mandeep Singh. This episode of the Tech Disruptors podcast looks at a w ...  Show more

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ...  Show more